This is not the most recent version of the article. View current version (30 APR 2013)

Intervention Protocol

Allopurinol for chronic gout

  1. Michelle Catton1,*,
  2. Naomi Schlesinger2,
  3. Xiaohong Zhou3,
  4. Ralph Schumacher4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 19 JUL 2006

DOI: 10.1002/14651858.CD006077

How to Cite

Catton M, Schlesinger N, Zhou X, Schumacher R. Allopurinol for chronic gout (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006077. DOI: 10.1002/14651858.CD006077.

Author Information

  1. 1

    Ottawa, Ontario, Canada

  2. 2

    UMDNJ - Robert Wood Johnson Medical School, Clinical Rheumatology, New Brunswick, NJ, USA

  3. 3

    University of Ottawa, Institute of Population Health, Ottawa, Canada

  4. 4

    Hospital of the University of Pennsylvania, Dept of Rheumatology, Philadelphia, Pennsylvania, USA

*Michelle Catton, 904-2035 Othello Ave., Ottawa, Ontario, K1G 3P6, Canada. mcatt077@uottawa.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 JUL 2006

SEARCH

This is not the most recent version of the article. View current version (30 APR 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1) To assess the efficacy and adverse effects of allopurinol versus placebo in suppressing gouty flares.

2) To assess the efficacy and adverse effects of allopurinol vs. other pharmacological agents in suppressing gouty flares.

3) To assess the efficacy and adverse effects of various regimens of allopurinol treatment in the suppression of gouty flares.